This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by O-Sullivan, I. Articles by Cohen, E. P. Search for Related Content PubMed PubMed Citation Articles by O-Sullivan, I. Articles by Cohen, E. P.

Immunity to Growth Factor Receptor–Bound Protein 10, a Signal Transduction Molecule, Inhibits the Growth of Breast Cancer in Mice

¹ Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, Illinois and ² School of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea

Requests for reprints: Edward P. Cohen, Department of Microbiology and Immunology (m/c 790), University of Illinois College of Medicine, 835 South Wolcott Avenue, Chicago, IL 60612. Phone: 312-996-9479; Fax: 312-996-6415; E-mail: EPCohen{at}UIC.EDU.

Key Words: Immunotherapy • Breast cancer • Grb10 • cDNA-based vaccine • Mouse

This study describes the application of a unique strategy to identify breast cancer antigens [tumor-associated antigen (TAA)]. In a mouse model, the strategy led to the identification of growth factor receptor–bound protein 10 (Grb10) as a newly identified TAA. Grb10 is a signal transduction molecule associated with multiple transmembrane tyrosine kinase receptors. It was discovered by comparing microarrays of cellular breast cancer vaccines highly enriched for cells that induced breast cancer immunity in tumor-bearing mice with nonenriched vaccines. The vaccines were prepared by transferring a cDNA expression library derived from SB5b cells, a breast cancer cell line C3H/He origin (H-2^k), into LM mouse fibroblasts (H-2^k). As the transferred cDNA integrates spontaneously into the genome of the recipient cells, replicates as the cells divide, and is expressed, the vaccine could be prepared from microgram amounts of tumor tissue. Relatively few cells in the transduced cell population, however, incorporated cDNA fragments that included genes specifying TAA. (The vast majority specified normal cellular constituents.) A unique strategy was used, therefore, to enrich the vaccine for immunotherapeutic cells. Twenty genes were overrepresented in the enriched vaccines. One, the gene for Grb10, was 100-fold overrepresented. To determine if Grb10 in the enriched vaccine was partly responsible for its therapeutic benefits, the gene was transferred into the fibroblast cell line, which was then used as a vaccine. Mice with established breast cancer treated solely by immunization with the modified fibroblasts developed robust immunity to the breast cancer cells, which, in some instances, was sufficient to result in tumor rejection. [Cancer Res 2008;68(7):2463–70]